Valsartan, Losartan, and Irbesartan
The Valsartan litigation consolidates claims that generic angiotensin-receptor-blocker blood-pressure medications — valsartan, losartan, and irbesartan — were contaminated with NDMA and NDEA, nitrosamine compounds classified as probable human carcinogens, allegedly elevating cancer risk among patients who took the affected generics. Structurally, this is a multi-manufacturer contamination litigation rather than a single-defendant drug case: because numerous generic manufacturers produced versions of these medications, the litigation must resolve manufacturer-specific liability and causation questions in addition to the general-causation dispute over whether the contaminants cause the cancers alleged.
That multi-manufacturer structure is likely the single largest driver of this docket's duration and resolution risk. Manufacturer attribution — confirming which company's product a given plaintiff actually took, over what period, and at what contamination level — must generally be resolved before a claim's broader causation and damages theory can be evaluated, which adds a layer of case-specific proof not present in a single-manufacturer drug MDL. With over fourteen hundred actions active roughly seven years into centralization, the docket has had substantial time to develop bellwether-style information on both attribution and causation questions across its claim population.
Resolution risk beyond attribution turns on how general-causation evidence for each alleged cancer type holds up, since nitrosamine-cancer causation science can vary by cancer type and exposure level, and on how claims against different manufacturers are sequenced for negotiated resolution or individual trial. Claims against manufacturers that settle earlier can also generate comparative pricing information useful for evaluating claims still pending against manufacturers that have not yet resolved their share of the docket.
Criterica Intelligence's regulated outcomes intelligence approach is built to make this kind of multi-defendant, multi-causation-theory structure legible — tracking attribution, causation, and sequencing dynamics without predicting a win rate or a dollar outcome for any claim — and applies the same discipline across every multi-manufacturer MDL in the federal docket, from contaminated-drug litigation like this one to multi-defendant device and consumer-product dockets.
It consolidates claims that generic valsartan, losartan, and irbesartan blood-pressure medications were contaminated with NDMA and NDEA, nitrosamine compounds linked to elevated cancer risk. Claims are centralized before Judge Renee M. Bumb in the District of New Jersey.
The contamination arose in the generic drug supply chain and affected products from numerous manufacturers rather than a single branded drug, which means the litigation must resolve manufacturer-specific liability questions in addition to general causation.
Manufacturer attribution for each claimant, the strength of general causation linking the contaminants to the specific cancers alleged, and how claims against different manufacturers are sequenced for bellwether development or settlement.
Yes. Criterica Intelligence's structural read captures how claim theories and resolution pathways can vary by defendant within a single MDL, rather than treating a multi-manufacturer docket as a single undifferentiated litigation.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.